Abstract
Inequities and gaps in palliative care access are a serious impediment to health systems especially low- and middle-income countries and the accurate measurement of need across health conditions is a critical step to understanding and addressing the issue. Serious Health-related Suffering (SHS) is a novel methodology to measure the palliative care need and was originally developed by The Lancet Commission on Global Access to Palliative Care and Pain Relief. In 2015, the first iteration – SHS 1.0 – was estimated at over 61 million people worldwide experiencing at least 6 billion days of SHS annually as a result of life-limiting and life-threatening conditions. In this paper, an updated methodology - SHS2.0 - is presented building on the work of the Lancet Commission and detailing calculations, data requirements, limitations, and assumptions. The updates to the original methodology focus on measuring the number of people who die with (decedents) or live with (non-decedents) SHS in a given year to assess the number of people in need of palliative care across health conditions and populations. Detail on the methodology for measuring the number of days of SHS that was pioneered by the Lancet Commission, is also shared, as this second measure is essential for determining the health system responses that are necessary to address palliative care need and must be a priority for future methodological work on SHS. The discussion encompasses opportunities for applying SHS to future policy making assessment of future research priorities particularly in light of the dearth of data from low- and middle-income countries, and sharing of directions for future work to develop SHS 3.0.
Competing Interest Statement
XJK reports consulting fees from University of Miami Institute for the Advanced of the Americas and consulting fees through a research grant from the Medical Research Council to the University of Edinburgh for work related to palliative care outside the submitted work. AB reports consulting fees from the University of Miami Institute for the Advanced Study of the Americas for part of the submitted work.
Funding Statement
We acknowledge support from the University of Miami and U.S. Cancer Pain Relief for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Joint first authors
↵‡ Joint last/senior authors
The revised manuscript has 6624 words, plus 7 tables, 2 panels and 123 references. We haveve now created a data appendix to house s,ome of the tables, a panel, and some sections that were in the manuscript so that the methodological flow is more focused in the main text. Please note that the data appendix only contains content that was previously in the manuscript; no new content was added.
Data Availability
As this paper is primarily methodological in nature, no additional data were generated for it. However, detailed descriptions of the methodology employed are provided to ensure reproducibility and transparency.
